Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

09.04.18	New Drugs Approved In March (RTTNews)
06.04.18	Incyte, Merck Stop Phase 3 Study Of Epacadostat In Combination With KEYTRUDA (RTTNews)
03.04.18	Will These Drugs Reach Blockbuster Status? (RTTNews)
03.04.18	AstraZeneca, Merck: European Medicines Agency To Review MAA For Lynparza (RTTNews)
02.04.18	Myriad Reports Approval For BRACAnalysis Diagnostic System In Japan (RTTNews)
01.04.18	An Ear To The Pharma: 5 Stocks To Watch This Week (RTTNews)
28.03.18	Biotech Stocks Facing FDA Decision In April (RTTNews)
27.03.18	Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan (PR Newswire)
27.03.18	Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan (PR Newswire)
26.03.18	Merck KGaA, Darmstadt, Germany webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference (PR Newswire)
26.03.18	Merck KGaA, Darmstadt, Germany webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference (PR Newswire)
23.03.18	Eisai, Merck: LENVIMA Approved For Additional Indication In Japan - Quick Facts (RTTNews)
21.03.18	S&P 500 Q4 2017 Buybacks Rose 6.0% to $137.0 Billion; Full-Year 2017 Fell 3.2% to $519.4 Billion (PR Newswire)
20.03.18	Merck KGaA, Darmstadt, Germany to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 22nd March 2018 (PR Newswire)
20.03.18	Merck KGaA, Darmstadt, Germany to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 22nd March 2018 (PR Newswire)
16.03.18	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 21st and 22nd, 2018 (PR Newswire)
16.03.18	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 21st and 22nd, 2018 (PR Newswire)
13.03.18	Merck: FDA Grants Priority Review To SBLA For KEYTRUDA - Quick Facts (RTTNews)
23.02.18	Merck Says LYNPARZA Receives Positive EU CHMP Opinion (RTTNews)
21.02.18	Merck To Buy Australia's Viralytics For $394 Mln In Cash - Quick Facts (RTTNews)
15.02.18	AstraZeneca: FDA Grants Orphan Drug Designation For Selumetinib - Quick Facts (RTTNews)
14.02.18	TTPH Implodes On IGNITE3, EC Approves 2nd Herceptin Biosimilar, PTIE At It Again (RTTNews)
13.02.18	Merck Discontinues APECS Study On Verubecestat Following EDMC Recommendation (RTTNews)
07.02.18	GILD's Sales Wane, SGMO Safe With CHAMPIONS, All's Not Well With Veterinarians? (RTTNews)
02.02.18	Merck Q4 Adj. Profit Tops View, But Sales Miss; Sees 2018 Adj. EPS In Line (RTTNews)
02.02.18	Merck & Co Inc. Announces Advance In Q4 Profit (RTTNews)
28.01.18	Viterra : 51 travailleurs en lock-out au Port de Montréal (PR Newswire)
19.01.18	AstraZeneca Announces Approval Of Lynparza In Japan - Quick Facts (RTTNews)
18.01.18	The Consumer Health of Merck Walks the Talk with its WE100 Movement (PR Newswire)
17.01.18	EIGR Disappoints, EXEL's CELESTIAL Excels, JUNO In CELG's Crosshairs? (RTTNews)
16.01.18	Merck's KEYTRUDA Significantly Improved Overall Survival And PFS (RTTNews)
14.01.18	AstraZeneca Says FDA Oks Lynparza For Metastatic Breast Cancer (RTTNews)
09.01.18	Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell... (PR Newswire)
08.01.18	Merck Says Phase 3 KEYTRUDA Trial Meets Primary Endpoint (RTTNews)
08.01.18	Merck Says FDA Accepts For Review Two NDAs For Doravirine - Quick Facts (RTTNews)
07.01.18	New Drugs Approved In December (RTTNews)
02.01.18	Merck Reports Approval Of KEYTRUDA For Urothelial Carcinoma In Japan (RTTNews)
24.12.17	It's Raining FDA Approvals, SMMT Opens Wallet, AGRX Snubbed Yet Again (RTTNews)
22.12.17	Merck, Pfizer: FDA Approves Steglatro And Fixed-dose Combination Steglujan (RTTNews)
21.12.17	FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma (PR Newswire)
14.12.17	PREVYMIS™ (letermovir) offert au Canada a la fin decembre 2017 pour la prophylaxie d'une infection a cytomegalovirus (CMV) chez les adultes seropositifs pour le CMV ayant recu une greffe de... (PR Newswire)
14.12.17	PREVYMIS™ (letermovir) Available in Canada in Late December 2017 for the Prophylaxis of Cytomegalovirus (CMV) Infection in Adult CMV-seropositive Recipients of an Allogeneic Hematopoietic Stem Cell... (PR Newswire)
12.12.17	Projet de cybersanté mentale visant à améliorer l'accès aux services de santé mentale à Terre-Neuve-et-Labrador pour ensuite ouvrir la voie à l'échelle nationale (PR Newswire)
08.12.17	New Drugs Approved In November (RTTNews)
30.11.17	Merck To Present New And Updated Data On KEYTRUDA, Updated Data On LYNPARZA (RTTNews)
29.11.17	Biotech Stocks Facing FDA Decision In December (RTTNews)
29.11.17	CytoSorbents to Present at the LD Micro Main Event Investor Conference (PR Newswire)
29.11.17	EARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark (RTTNews)
13.11.17	Merck Gets Positive CHMP Opinion For Prevymis In EU - Quick Facts (RTTNews)
09.11.17	Merck Gets FDA Approval Of Prevymis For Prevention Of CMV Infection (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11.12.24		Dow Jones-Handel aktuell: Dow Jones verbucht letztendlich Verluste
11.12.24		Schwache Performance in New York: Dow Jones gibt nachmittags nach
11.12.24		Gewinne in New York: Dow Jones verbucht am Mittwochmittag Zuschläge
11.12.24		Börse London: FTSE 100 zum Ende des Mittwochshandels mit positivem Vorzeichen
11.12.24		Starker Wochentag in Europa: STOXX 50 klettert zum Handelsende

11.12.24

Dow Jones-Handel aktuell: Dow Jones verbucht letztendlich Verluste

11.12.24

Schwache Performance in New York: Dow Jones gibt nachmittags nach

11.12.24

Gewinne in New York: Dow Jones verbucht am Mittwochmittag Zuschläge

11.12.24

Börse London: FTSE 100 zum Ende des Mittwochshandels mit positivem Vorzeichen

11.12.24

Starker Wochentag in Europa: STOXX 50 klettert zum Handelsende

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten